In the recently published HARMONi-A (AK112-301) study, ivonescimab, an anti-PD-1/VEGF bispecific antibody, plus chemotherapy significantly improved PFS (7.06 months vs 4.80 months with placebo) with a manageable safety profile in patients with NSCLC previously treated with EGFR TKI [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.